Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature

Christophe Nicol1 Karine Lacut2,3 Brigitte Pan-Petesch1,3 Eric Lippert4,5 Jean-Christophe Ianotto1,3,5

1 Service d’Hémato Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Bretagne, France
2 Département de Médecine Interne et Pneumologie, CHRU de Brest, Bretagne, France
3 GETBO, Groupe d’Etude de la Thrombose de Bretagne Occidentale, CHRU de Brest, Bretagne, France
4 Laboratoire d’Hématologie, CHRU de Brest, Bretagne, France
5 FIM, France Intergroupe des Néoplasies Myéloprolifératives, France

Address for correspondence Christophe Nicol, MD, Service d’Hémato Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, 29200 Bretagne, France (e-mail: christophe.nicol@chu-brest.fr).

Abstract

Hemorrhage is a well-known complication of essential thrombocythemia (ET) and polycythemia vera (PV), but evidence-based data on its management and prevention are lacking to help inform clinicians. In this review, appropriate published data from the past 15 years regarding bleeding epidemiology, classification, location, and risk factors are presented and discussed. Research was conducted using the Medline database. The bleeding classifications were heterogeneous among the collected studies. The median incidences of bleeding and major bleeding were 4.6 and 0.79% patients/year, in ET patients and 6.5 and 1.05% patients/year in PV patients, respectively. The most frequent location was the gastrointestinal tract. Bleeding accounted for up to 13.7% of deaths, and cerebral bleeding was the main cause of lethal hemorrhage. Thirty-nine potential risk factors were analyzed at least once, but the results were discrepant. Among them, age >60 years, bleeding history, splenomegaly, myeloproliferative neoplasm subtype, and platelet count should deserve more attention in future studies. Among the treatments, aspirin seemed to be problematic for young patients with ET (especially CALR-mutated ET patients) and anagrelide was also identified as a bleeding inducer, especially when associated with aspirin. Future studies should analyze bleeding risk factors in more homogeneous populations and with common bleeding classifications. More tools are needed to help clinicians manage the increased risk of potentially lethal bleeding events in these diseases.

Keywords
► essential thrombocythemia
► polycythemia vera
► bleeding
► risk factors
► classification

Introduction

Myeloproliferative neoplasms (MPNs) are a group of hematological malignancies individualized in the 2016 World Health Organization (WHO) classification.1 They are subdivided into two groups: chronic myeloid leukemia and Philadelphia-negative MPNs, which are further divided into essential thrombocythemia (ET), polycythemia vera (PV), primitive myelofibrosis (PMF), and prefibrotic myelofibrosis. Philadelphia-negative MPNs are characterized by the chronic proliferation of myeloid cells in bone marrow and three main clonal mutations.1 Life expectancy is reduced due to the increased rate of thrombosis and hemorrhage2 and risk of hematological transformation into acute myeloid leukemia and/or secondary myelofibrosis.2 Up to 39% of patients will suffer from arterial and/or venous thrombosis throughout...
the course of ET or PV. Recent guidelines focus mainly on reducing the thrombotic risk.

Hemorrhages are less frequent than thrombosis in MPNs and have been found in 3 to 18% of ET and 3 to 8.1% of PV cases. They are mostly described as a consequence of acquired von Willebrand syndrome (AWS) or in the presence of thrombocytopenia, MPN-associated thrombopathy, and/or antithrombotic drug use. MPN studies usually focus on thrombosis and give few details about bleeding. A recent review on thrombosis and bleeding complications in MPNs underlined the lack of evidence-based data to support guidelines for the prevention and management of bleeding in MPN patients.

In this review, data from the literature concerning bleeding epidemiology, locations, and risk factors, particularly in ET and PV patients, are presented and discussed.

Methods

Data Sources and Research
We searched English and French articles from 2004 to 2018 in the Medline database and referenced the terms myeloproliferative syndrome, myeloproliferative neoplasm, polycythemia vera, and essential thrombocytopenia, in combination with either bleeding or hemorrhage. Reviews with unreleased data, prospective/retrospective observational studies, and clinical trials were collected and relevant references of these articles were also searched. Case reports, editorials, and reviews with published data were excluded.

Studies had to provide data about at least one of the following features: epidemiology of bleeding, classification of bleeding severity, location of bleeding, antithrombotic treatment at diagnosis or at the time of hemorrhage, and bleeding risk factors.

Studies were included if they reported patients with PV or ET, regardless of whether patients with other MPNs were included. In studies including patients with other MPNs, only data about ET/PV epidemiology and location are presented, if distinguishable.

All the publications included in this review concerned adult patients.

Definitions and Analyses of Hemorrhagic Events
Data on the incidence and location are presented according to “major bleeding” (MB) event or “any bleeding” event, as provided by each study. “Major hemorrhages” and “severe bleeding or hemorrhage” were considered MB events.

If the Common Terminology Criteria for Adverse Events (CTCAE) were used with no dissociation between MB and non-MB events, grade 3, 4, and 5 events were considered MB.

In most recent studies of bleeding in the general population, definitions used for bleeding severity are those of the International Society of Thrombosis and Hemostasis (ISTH), and we analyzed whether definitions observed in our review were in concordance with ISTH definitions.

According to ISTH, MB was defined in 2005 as fatal bleeding and/or symptomatic bleeding in critical areas or organs, such as intracranial, intraocular, intraspinal, retroperitoneal, intra-articular, pericardial, or intramuscular bleeding with compartment syndrome and/or bleeding causing a decline in the hemoglobin level of 2 g/dL or more or leading to the transfusion of two or more units of whole blood or red blood cells. In 2015, ISTH defined clinically relevant non-MB (CRNMB) events as hemorrhages that did not meet MB criteria but met at least one of the following criteria: required medical intervention by a health care professional, unscheduled hospitalization, increased level of care, or a face-to-face evaluation.

Statistical Analysis

The incidence of bleeding events was calculated and reported as both the raw incidence and incidence of bleeding per 100 patient-years. Patient-years were calculated by multiplying the median follow-up duration by the number of patients in the study. Bleeding events per 100 patient-years were calculated by dividing the raw incidence of bleeding (percentage) by the median follow-up duration.

Results

Literature Search
The study selection process is detailed in Fig. 1. The first step led to 1,266 potentially eligible articles. After review according to the prespecified inclusion and exclusion criteria, 38 articles were selected for further analysis.

Nineteen retrospective studies provided data about MPN patients, including non-ET/PV patients. The proportion of non-ET and non-PV populations ranged from 3.2 to 33.4% in 12 studies, and this subgroup corresponded mainly to patients with PMF. Raw data extracted from these studies concerning the incidence and location of bleeding are shown in Supplementary Table S1 (available in the online version).

Fig. 1 Flowchart of the review of literature on hemorrhagic complications in ET and/or PV. ET, essential thrombocytopenia; PV, polycythemia vera.
Incidence of Hemorrhages

Twelve articles, including two randomized comparative studies and one phase IV study, focused on ET, with cohorts ranging from 110 to 809 patients, and a median follow-up ranging from 2.6 to 13.6 years. A total of 10,370 patients with ET were followed for a median time of 5 years. Bleeding events of any severity were included with an incidence ranging from 1.39 to 6.6 per 100 patient-years. The incidence rate of MB events was 0.43 to 5.3 per 100 patient-years. The two highest incidences were reported in one study in which patients received a vitamin K antagonist (VKA) and another study with less stringent MB criteria.

Seven studies, including three randomized comparative studies, focused only on PV, with cohorts ranging from 155 to 1,638 patients, and a median follow-up ranging from 1.6 to 16.3 years. In the PV literature, a total of 5,683 patients were followed for a median time of 4.8 years. The incidence rate of MB events ranged from 0.3 to 5.3 per 100 patient-years. Bleeding events of all types were included with an incidence ranging from 0.1 to 5.64% patients/year.

Table 1: Incidences of hemorrhages depending on their severity during the follow-up of ET patients

<table>
<thead>
<tr>
<th>Year</th>
<th>First author</th>
<th>n</th>
<th>Median FU (y)</th>
<th>Incidence of hemorrhages (during follow-up and 100 pts/y)</th>
<th>Incidence of major bleedings (during follow-up and 100 pts/y)</th>
<th>Incidence of lethal bleedings</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Harrison</td>
<td>32</td>
<td>809</td>
<td>3.3</td>
<td>9.2 and 2.83% pts/y</td>
<td>13.7%</td>
</tr>
<tr>
<td>2005</td>
<td>Chim</td>
<td>33</td>
<td>231</td>
<td>ND</td>
<td>6.5%</td>
<td>-</td>
</tr>
<tr>
<td>2006</td>
<td>Wolanskyj</td>
<td>34</td>
<td>322</td>
<td>13.6</td>
<td>11.9% at 10 y, 15.1% at 15 y</td>
<td>-</td>
</tr>
<tr>
<td>2007</td>
<td>Radaelli</td>
<td>35</td>
<td>306</td>
<td>8</td>
<td>10.1 and 1.26% pts/y</td>
<td>1.5%</td>
</tr>
<tr>
<td>2010</td>
<td>Alvarez-Larrán</td>
<td>36</td>
<td>300</td>
<td>5.5</td>
<td>5 and 0.9% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2012</td>
<td>Finazzi</td>
<td>15</td>
<td>891</td>
<td>6.2</td>
<td>6.3 and 0.79% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2012</td>
<td>Palandri</td>
<td>37</td>
<td>565</td>
<td>7.8</td>
<td>10.8 and 1.39% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2012</td>
<td>Campbell</td>
<td>38</td>
<td>776</td>
<td>3</td>
<td>3.9 and 0.5% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2013</td>
<td>Chou</td>
<td>16</td>
<td>146</td>
<td>3</td>
<td>19.9 and 6.6% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2013</td>
<td>Gisslinger</td>
<td>41</td>
<td>259</td>
<td>ND</td>
<td>26%</td>
<td>4.57%</td>
</tr>
<tr>
<td>2015</td>
<td>Lim</td>
<td>19</td>
<td>69</td>
<td>4.5</td>
<td>16.7 and 3.7% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2015</td>
<td>Kander</td>
<td>17</td>
<td>144</td>
<td>5</td>
<td>10.4 and 2.1% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2015</td>
<td>Hernández-Boluda</td>
<td>52</td>
<td>71</td>
<td>7.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2015</td>
<td>Duangnopasatit</td>
<td>40</td>
<td>83</td>
<td>ND</td>
<td>10.8%</td>
<td>-</td>
</tr>
<tr>
<td>2016</td>
<td>Khan</td>
<td>21</td>
<td>52</td>
<td>6</td>
<td>13.5 and 2.25% pts/y</td>
<td>-</td>
</tr>
<tr>
<td>2016</td>
<td>Kafie</td>
<td>42</td>
<td>159</td>
<td>ND</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2017</td>
<td>Rottenstreich</td>
<td>34</td>
<td>116</td>
<td>ND</td>
<td>51.7%</td>
<td>-</td>
</tr>
<tr>
<td>2016</td>
<td>Alvarez-Larrán</td>
<td>39</td>
<td>433</td>
<td>5.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2017</td>
<td>Rumi</td>
<td>40</td>
<td>404</td>
<td>5</td>
<td>19.6 at 10 y</td>
<td>-</td>
</tr>
<tr>
<td>2017</td>
<td>Harrison</td>
<td>40</td>
<td>110</td>
<td>2.6</td>
<td>5.5 and 2.11% pts/y</td>
<td>1.82 and 0.7% pts/y</td>
</tr>
<tr>
<td>2018</td>
<td>Kamiuntingen</td>
<td>28</td>
<td>117</td>
<td>3.9</td>
<td>7.7 and 1.98% pts/y</td>
<td>1.7 and 0.44% pts/y</td>
</tr>
<tr>
<td>2018</td>
<td>Godfrey</td>
<td>30</td>
<td>358</td>
<td>6.1</td>
<td>17 and 2.8% pts/y</td>
<td>2.8 and 0.46% pts/y</td>
</tr>
<tr>
<td>2018</td>
<td>Birgégard</td>
<td>31</td>
<td>3,649</td>
<td>5</td>
<td>-</td>
<td>0.89 pts/y (anagrelide) and 0.43% pts/y (other cytoreductive drugs)</td>
</tr>
<tr>
<td></td>
<td>Median (ET)</td>
<td></td>
<td>259</td>
<td>5.1</td>
<td>12.5 and 2.18% pts/y</td>
<td>4.57 and 0.79% pts/y</td>
</tr>
</tbody>
</table>

Abbreviations: ET, essential thrombocythemia; FU, follow-up; pts/y, patients/year; n, number of patients; ND, not detailed.

Note: Year and author in italic mean that the article studied several myeloproliferative neoplasm types. Difference of population size was not considered for median value calculation.
In ET patients, 326 episodes of bleeding were described in 13 studies.\(^{15,16,20,23,24,28,30,32,33,35,37,40,41}\) Four subdural and three intracranial hemorrhages were described in ET patients.\(^{16}\) We extracted 190 MB episodes in ET patients.\(^{15,16,24,28,30,32,35,37,40,41}\) (\(\textbf{Fig. 2A}\)).

**Table 2 Incidences of hemorrhages depending on their severity during the follow-up of PV patients**

<table>
<thead>
<tr>
<th>Year</th>
<th>First author</th>
<th>n</th>
<th>Median FU (y)</th>
<th>Incidence of hemorrhages (during follow-up and 100 pts/y)</th>
<th>Incidence of major bleedings (during follow-up and 100 pts/y)</th>
<th>Incidence of lethal bleedings</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>Landoi(^{14})</td>
<td>518</td>
<td>3</td>
<td>7.1 and 2.37% pts/y</td>
<td>0.9 and 0.3% pts/y</td>
<td>–</td>
</tr>
<tr>
<td>2005</td>
<td>Marchiol(^{46})</td>
<td>1,638</td>
<td>2.7</td>
<td>7.8 and 2.9% pts/y</td>
<td>2.2 and 0.8% pts/y</td>
<td>4.3%</td>
</tr>
<tr>
<td>2011</td>
<td>Kiladjian(^{64})</td>
<td>285</td>
<td>16.3</td>
<td>1.7 and 0.1% pts/y</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2013</td>
<td>Tefferi(^{3})</td>
<td>1,545</td>
<td>6.9</td>
<td>–</td>
<td>4.2 and 0.61% pts/y</td>
<td>1.4%</td>
</tr>
<tr>
<td>2013</td>
<td>Chou(^{16})</td>
<td>101</td>
<td>3</td>
<td>24 and 8% pts/y</td>
<td>16 and 5.3% pts/y</td>
<td>–</td>
</tr>
<tr>
<td>2015</td>
<td>Vannucchi(^{45})</td>
<td>221</td>
<td>1.6</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2015</td>
<td>Kander(^{37})</td>
<td>118</td>
<td>5</td>
<td>15.3 and 3.1% pts/y</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2015</td>
<td>Lim(^{19})</td>
<td>33</td>
<td>4.5</td>
<td>15.8 and 3.5% pts/y</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2015</td>
<td>Hernández-Boluda(^{12})</td>
<td>79</td>
<td>7.7</td>
<td>–</td>
<td>7.7 and 1.3% pts/y</td>
<td>–</td>
</tr>
<tr>
<td>2015</td>
<td>Duangnapasatit(^{20})</td>
<td>68</td>
<td>ND</td>
<td>7.4%</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2016</td>
<td>Khan(^{21})</td>
<td>52</td>
<td>6</td>
<td>15.4 and 2.6% pts/y</td>
<td>7.7 and 1.3% pts/y</td>
<td>–</td>
</tr>
<tr>
<td>2016</td>
<td>Kaife(^{23})</td>
<td>164</td>
<td>ND</td>
<td>–</td>
<td>10.3%</td>
<td>–</td>
</tr>
<tr>
<td>2017</td>
<td>Rottenstreich(^{24})</td>
<td>57</td>
<td>ND</td>
<td>36.8%</td>
<td>5.3%</td>
<td>–</td>
</tr>
<tr>
<td>2017</td>
<td>Yesilova(^{47})</td>
<td>155</td>
<td>5.5</td>
<td>31 and 5.64% pts/y</td>
<td>7.7 and 1.4% pts/y</td>
<td>8%</td>
</tr>
<tr>
<td>2017</td>
<td>Cerquozzi(^{48})</td>
<td>587</td>
<td>9.1</td>
<td>–</td>
<td>4 and 0.44% pts/y</td>
<td>–</td>
</tr>
<tr>
<td>2018</td>
<td>Kamiunten(^{28})</td>
<td>62</td>
<td>3.3</td>
<td>6.5 and 1.94% pts/y</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Median (PV)</td>
<td>136.5</td>
<td>4.5</td>
<td>15.3 and 2.9% pts/y</td>
<td>6.5 and 1.05% pts/y</td>
<td>4.3%</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: FU, follow-up; pts/y, patients/year; ND, not detailed; PV, polycythemia vera.

Note: Year and author in italic mean that the article studied several myeloproliferative neoplasm types. Difference of population size was not considered for median value calculation.

(“ISTH-Like”) that had some differences concerning the location, number of transfusions, and/or hemoglobin decline needed to define a MB. The WHO bleeding scale\(^{14,29}\) and the CTCAE classification\(^{17,40,49}\) included bleeding severity ranging from minor to lethal, and were both used twice. Bleeding severity definitions were unclear in 10 articles.

In most cases, either MB or every hemorrhage event was included. In that instance, bleeding was defined as either MB or minor bleeding event. Minor bleeding events were mostly defined as any bleeding event that did not fulfill MB criteria. Only one study used the concept of a CRNMB, which had a definition similar to that of the ISTH.\(^{10,19}\)

**Location of Bleeding Events**

Locations of bleeding are often not described. Data from ET and PV patients were dissociated from pooled data of MPNs (\(\textbf{Supplementary Table S4}\) [available in the online version]). When specified, data concerning MB were separately analyzed, to assess these potentially life-threatening events independently from other hemorrhages. Data about lethal bleeding were rare.

In ET patients, 326 episodes of bleeding were described in 13 studies.\(^{15,16,20,23,24,28,30,32,33,35,37,40,41}\) (\(\textbf{Fig. 2A}\)). The gastrointestinal tract (GIT; 40.8%) and the mouth, nose, and throat (MNT: 12.2%) were the most frequent locations. Of note, 3.4% of episodes were postoperative bleeding. Two subdural and four intracranial hemorrhages were described in ET patients.\(^{16}\) We extracted 190 MB episodes in ET patients.\(^{15,16,24,28,30,32,35,37,40,41}\) (\(\textbf{Fig. 2B}\)). The GIT was again the most frequent site of bleeding (54.7%). Only 16 fatal bleeding events were described.\(^{13,16,30,32,35-37,40}\) Three central nervous system (CNS) bleeding cases were individualized (18.8%).\(^{13,30,40}\) Details were unavailable for the others.

In PV patients, seven studies reported the location of 157 bleeding episodes in a PV population.\(^{16,20,23,24,28,43,47}\) (\(\textbf{Fig. 2C}\)). The most frequent location was the GIT, found in 35.7% of cases. MNT and mucocutaneous (without precision) locations of bleeding were frequent, both representing 17.2% of cases. Only one study described CNS bleeding locations, with four subdural and three intracranial hemorrhages.\(^{16}\) The location of MB was rarely available in PV patients. Three articles analyzed 25 MB events, mainly concerning the GIT (48%) and the CNS (44%) (\(\textbf{Fig. 2D}\)). Twenty-one lethal bleeding events of PV patients were individualized in this review.\(^{5,13,16,17,43,45-47}\) Locations were the CNS in four cases (19%), the GIT in one (4.8%)\(^{43,45,46}\), “other” in five cases (23.8%)\(^{46}\), and undetailed in all other cases.

In total, among the 37 lethal events identified, only eight (21.6%) were described, and seven (18.9%) were CNS bleeding. Hemorrhages represented a limited proportion of death, accounting for 1.4 to 8% for PV patients\(^{3,46,47}\) and 1.5 to 13.7% for ET patients.\(^{30,32,35}\) Most importantly, the case fatality rate of MB ranged from 3.1 to 26.7% of cases.\(^{1,3,30,32,35,37,46,47}\) In total, 20.6% (35/170) of MB events led to death.
Postoperative Bleeding

Postoperative bleeding was mentioned in only six studies, and 21 episodes were described, out of 220 hemorrhages (9.6%). Interestingly, eight were secondary to dental extraction. Others were not described and just labeled “postoperative” (►Supplementary Table S5 [available in the online version]).

One study focused on this subject, with a total of 255 ET or PV patients who underwent 311 surgeries. MB events were defined according to the ISTH criterion. Major and minor bleedings events occurred in 7.3 and 2.3% of surgeries, respectively. The authors concluded that there is an increased risk of thrombosis and hemorrhages in surgeries of MPN patients.

Clinical Risk Factors

Thirty-two articles analyzed 39 potential risk factors in the MPN population. PV-focused studies presented 11 potential bleeding risk factors, whereas ET-focused studies showed 24 potential risk factors. One article analyzed 17 potential risk factors.

Seventeen clinical risk factors have been analyzed in the literature (►Table 3). Seven were analyzed only once. The most extensively studied was age (mostly >60 years), but 11 studies did not lead to any consensus.

Duration of disease, hypertension, thrombosis, and bleeding history were often considered bleeding risk factors. With the exception of hypertension, arterial cardiovascular risk factors were not bleeding risk factors. Interestingly, splenomegaly was associated with a significant odds ratio (OR: 2.22–7.6) in several studies. Lastly, male gender was once found to be a bleeding risk factor with a relatively high OR of 3.74, but there was no significant impact of gender on bleeding risk in six other analyses.
Biological Risk Factors

Thirteen potential biological risk factors are shown in Table 4. The MPN type was studied in six articles,\(^ {15-17,23,24,47}\) with various comparisons. Compared with ET, PV was considered by itself to be a bleeding risk factor in one out of three studies,\(^ {16,17,23}\) and one article provided an OR (ET vs. PV: OR = 0.34).\(^ {23}\) The JAK2 mutation was analyzed 10 times but was only twice reported as a risk factor, including in one study featuring composite criteria with platelet values.\(^ {14-17,19,24,36,37,39}\) Elevated JAK2 allele burden was found in one out of two analyses as a discriminant among JAK2-mutated PV patients.\(^ {27}\) Two studies analyzed the impact of CALR mutations,\(^ {17,39}\) but only one concluded there was an increased bleeding risk if CALR-mutated ET patients were taking aspirin.\(^ {39}\)

Baseline platelet and leukocyte values were also frequently analyzed. The platelet-threshold > 1,000 G/L seemed consensual (three studies pro, one trending pro, and one against),\(^ {15,16,22,31,37}\) with two hazard ratio (HR) values provided (2.3 and 2.36).\(^ {31,37}\) Leukocyte counts were identified as risk factors in three out of 10 studies but with various thresholds.\(^ {15-17,21,22,33,36-38,47}\) This risk seemed higher when leukocyte counts increased (> 11 G/L, HR = 1.9 or 1.74\(^ {15,37}\); > 16 G/L, OR = 3.19).\(^ {16}\)
<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Number of articles</th>
<th>$p$ &lt; 0.05 or considered significant by the authors</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MPN disease</strong></td>
<td>6(^{15-17,23,24,47})</td>
<td>4(^{15,23,24,47})</td>
<td>PreMF vs. ET: OR = 1.74 (1–3.06), JAK2 mutated ET vs. other ET and PV, one post-PV myelofibrosis vs. PV: OR = 2.6 (1.0–6.8), and ET vs. PV: OR = 0.34 (0.13–0.91)</td>
</tr>
<tr>
<td><strong>Baseline complete blood count</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platelets</strong></td>
<td>11(^{15-17,20,22,31,33,36-38,47})</td>
<td>6(^{20,22,31,33,36,37})</td>
<td>Positive thresholds tested (if detailed): &gt;800 G/L(^{36}), IRR = 10.6 (1.7–69), (&gt;1,000) G/L(^{22,31,37}), HR: 2.3 (1.3–3.7) in univariate analysis, but still significant in multivariate, (&gt;1,200) G/L(^{33}) No threshold detailed: &quot;platelets count&quot;: OR (PV) = 1.01 (1.00–1.01)(^{10}) Negative threshold tested: &gt;800, 1,000, 1,200, and 1,500 G/L(^{15}), &gt;1,000 G/L(^{16})</td>
</tr>
<tr>
<td><strong>Leukocytes</strong></td>
<td>10(^{15-17,21,22,33,36-38,47})</td>
<td>3(^{15,16,37})</td>
<td>Positive thresholds tested: &gt;11 G/L(^{15,37}), HR = 1.74 (1.02–2.97), (&gt;16) G/L(^{16}); OR = 3.19 (1.62–6.25) in multivariate analysis. Negative threshold tested: &gt;8.7, &gt;10, 11 G/L(^{33}) Significant for both PV and ET in univariate analysis, but for PV in multivariate analysis(^{33})</td>
</tr>
<tr>
<td><strong>Hemoglobin/hematocrit</strong></td>
<td>6(^{22,36-38,47})</td>
<td>1(^{22})</td>
<td>–</td>
</tr>
<tr>
<td><strong>Mean platelet volume</strong></td>
<td>1(^{29})</td>
<td>1</td>
<td>Positive for major bleeding (10.04 vs. 8.6 fl) Negative for &quot;bleeding episode of any grade&quot; Negative in multivariate analysis</td>
</tr>
<tr>
<td><strong>Complete blood count at bleeding</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platelets</strong></td>
<td>3(^{23,36,38})</td>
<td>2(^{18,39})</td>
<td>A nonlinear increase of HR once platelets &gt;450 G/L(^{38}) Negative threshold used: &gt;1,000 G/L and &lt;100 G/L(^{23}) and &gt;1,000 G/L + CALR mutation(^{19}) Positive threshold used: &gt;1,000 G/L + JAK2 mutation(^{30}), IRR = 9.8 (2.3–42.3)(^{39})</td>
</tr>
<tr>
<td><strong>Leukocytes</strong></td>
<td>2(^{38,39})</td>
<td>1</td>
<td>A nonlinear increase of HR when leucocyte count increases(^{16})</td>
</tr>
<tr>
<td><strong>Hemoglobin/hematocrit</strong></td>
<td>1(^{38})</td>
<td>1</td>
<td>Low hemoglobin count</td>
</tr>
<tr>
<td><strong>Mean platelet volume</strong></td>
<td>1(^{29})</td>
<td>1</td>
<td>Positive for major bleeding (9.37 vs. 8.62 fl) Negative for &quot;bleeding episode of any grade&quot; Negative in multivariate analysis</td>
</tr>
<tr>
<td><strong>Acquired Willebrand syndrome</strong></td>
<td>1(^{24})</td>
<td>1</td>
<td>Criteria for diagnosis: VWF:RCo &lt; 41 or 58% (in O and non-O blood groups), VWF:RCo/VWF: Ag &lt; 0.7 and negative family history of von Willebrand disease</td>
</tr>
<tr>
<td><strong>Mutations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>JAK2 mutation</strong></td>
<td>8(^{15-18,24,36,39})</td>
<td>2(^{24,39})</td>
<td>Positive for JAK2 + ET,(^{24}) and JAK2 + ET plus platelets &gt;1,000 G/L(^{39}); IRR = 9.8 (2.3–42.3)(^{39}) Negative if analyzed alone(^{15–18,36,37}) or associated with antiplatelets(^{36})</td>
</tr>
<tr>
<td><strong>JAK2 allele burden</strong></td>
<td>2(^{18,27})</td>
<td>1(^{27})</td>
<td>Positive threshold: &gt;75%(^{27}); negative threshold: &lt;20%(^{18})</td>
</tr>
<tr>
<td><strong>CALR mutation</strong></td>
<td>2(^{17,39})</td>
<td>1(^{39})</td>
<td>CALR+ MPN(^{17}) and association of CALR + ET with antiplatelet therapy(^{39})</td>
</tr>
<tr>
<td><strong>Albumin</strong></td>
<td>1(^{16})</td>
<td>1</td>
<td>Albumin &lt; 40 g/L: OR = 2.37 (1.18–4.79)(^{16})</td>
</tr>
</tbody>
</table>

Abbreviations: ET, essential thrombocythemia; HR, hazard ratio; IRR, incidence rate ratio; MPN, myeloproliferative neoplasm; OR, odds ratio; preMF, prefibrotic myelofibrosis; PV, polycythemia vera; VWF:Ag, von Willebrand factor antigen; VWF:RCo, von Willebrand factor ristocetin cofactor.
Only one study that statistically analyzed AWS confirmed it to be a bleeding risk factor.

**Antithrombotic and Cytoreductive Drugs**

Antithrombotic drugs are frequently associated with an increased risk of bleeding in the general population, thus they have been studied as potential bleeding risk factors in MPNs (Table 5). Aspirin intake was extensively studied, with discordant results. In the only prospective trial in this field in MPN patients, the ECLAP study, PV patients were prospectively randomized into aspirin versus placebo treatments as primary thrombosis prophylaxis. Minor and MB events were more frequent in the aspirin group (9.1 vs. 5.3%), but the difference was not statistically significant (risk ratio = 1.82, p = 0.08). Interestingly, one study showed an increased risk of hemorrhages in a young population of CALR-mutated ET compared with JAK2-mutated patients. VKAs in MPN patients were studied less, and no statistical difference was found. Unfractionated heparin was analyzed once, as a potent bleeding risk factor (OR = 5.64). No other antithrombotic drugs can be clearly linked to hemorrhage in MPNs. Direct oral anticoagulants (DOACs) did not increase bleeding risk compared with aspirin in a case-control study.

Information about antithrombotic drug use at diagnosis and at the time of hemorrhage was collected (Supplementary Table S6 [available in the online version]). Information on PV and ET cases was not easily extractable from articles and reviews. At diagnosis, data were at least partially available in eight studies, for a total of 4,159 patients. Patients mostly received antiplatelet agents (57.5%), but 3.8% received anticoagulant drugs. Data were unavailable for 32.3% of cases. Regarding the time of the bleeding episode, data were partially available in six studies, for a total of 2,089 patients. Antiplatelet agents were the major drug class used (66.2%), whereas 6.2% received anticoagulant drugs. Data were unavailable for 13.3% of cases.

Cytoreductive drugs have been analyzed as potential bleeding risk factors (Table 5). Hydroxyurea is the most used cytoreductive drug. It has never been identified as a bleeding risk drug. Prospectively compared with hydroxyurea, anagrelide increased bleeding risk. Retrospectively, anagrelide in combination with low-dose aspirin seemed to increase bleeding risk compared with anagrelide alone. Ruxolitinib did not increase bleeding risk in a prospective study with a follow-up of 1 year. No data are available for pipobroman, interferon, or busulfan.
Discussion

The most recent reviews on bleeding of MPN patients present a prevalence at diagnosis and an incidence during follow-up of 7.3 and 9% in ET and 6.9 and 8% in PV, respectively.9,57,58 Thrombotic complications remain more frequent in this population (up to 39% of patients3,4) compared with the general population, but hemorrhagic risk should not be underestimated due to the high rate of morbidity/mortality. Particularly, the case fatality rate from MBs of 20.6% (35/170 events) in ET and PV patients must be underscored. In comparison, results from a recent meta-analysis in cancer patients treated with anticoagulant drugs found a case fatality rate of MBs of 8.9%(95 confidence interval: 3.5–21.1%).39 This may explain why MPN patients with hemorrhage have a lower overall survival than patients without hemorrhage.36

Currently, management of PV and ET patients is based on European Leukemia Network (ELN) criteria for thrombotic risk evaluation (age over 60 years and/or history of thrombosis). Interestingly, patients with platelet counts over 1,500 G/L are also considered high-risk patients, because of increased bleeding risk. There is no specific score of hemorrhage in MPNs.

Studies and cohorts are difficult to compare because of the heterogeneity of bleeding classifications (ISTH, CTCAE, WHO, etc.) and populations (multiple MPNs). This heterogeneity was noted in a 2017 review on ET patients,60 and it remained true in 2019 for both ET and PV patients. Only half of the studies used adapted ISTH definitions or similar definitions for MB. The CRNMB definition was published in 2015, but only one study used it.10,19 Regardless, minor bleedings events and CRNMB were mostly merged and reported as a unique entity, even in recent studies. In our opinion CRNMB is of interest. Indeed, it is associated with an increased risk of morbidity, whereas MB is associated with potential mortality.

Thirty-nine potential risk factors were analyzed at least once, but the results were contradictory. Among them, age >60 years, bleeding history, splenomegaly, MPN subtype, and platelet count could deserve more attention in future studies.

Among the causes of increased bleeding risk in ET and PV patients, AWS was frequently cited, although it was only analyzed once as a bleeding risk factor.24 The incidence of AWS was quite high in this study (55% in ET and 49% in PV).24 compared with other studies (20% in TE61 and 12% in PV patients62). The diagnostic criteria of AWS are not universal, and these studies used different criteria. For example, different VWF:RCo/Ag ratio thresholds of 0.661,62 and 0.724 were used as one of diagnostic criteria of AWS. Another explanation of the difference of incidence could be the time between ET diagnosis and AWS testing, as it was longer in the two studies with lower incidence of AWS61,62 possibly due to more stable hematological situations. Importantly, AWS was mostly found with platelets under 1,000 G/L, and it even presents with normal platelets.24,61 A higher leukocyte count was associated with more AWS in PV patients.62 The hemoglobin/hematocrit level also predicted the development of AWS in ET patients,46,61 and in PV patients in one study.62 It may be a consequence of increased blood viscosity associated with higher hematocrit63 and leukocytes,64 with qualitative abnormalities leading to high shear stress and increased proteolysis, particularly of high molecular-weight multimers of VWF.55 Blood count thresholds leading to the development of AWS are probably extremely variable between patients, so AWS should be systematically assessed at diagnosis; the evaluation of AWS could be repeated during follow-up until it normalized. It could also be done when bleeding and thrombosis occur and before surgeries. Tranexamic acid could be a valid option to reduce spontaneous and provoked bleeding.65 In the end, few studies focused on this frequently cited complication of MPN, and it deserves more attention.

Among cytoreductive drugs, anagrelide probably increases bleeding risk compared with hydroxyurea,18,31,32 particularly if administered with aspirin (PT1 prospective trial),31 even though one prospective trial (ANAHYDRET) did not find any difference between hydroxyurea and anagrelide.31 Thus, anagrelide is not recommended as a first-line treatment in ET patients.56 Hydroxyurea was compared with no cytoreduction in only one study, with no difference in bleeding risk observed.30

On the other hand, antiplatelet drugs are the most frequent drugs used, and prescriptions are adapted to ELN recommendations. It is difficult to assess their bleeding risk as most patients take aspirin as primary or secondary prophylaxis or anticoagulants as secondary prophylaxis. As a reminder, MPN patients are mostly elderly and aspirin was prospectively found to increase bleeding risk when used for the primary prevention of cardiovascular disease of 19,114 elderly patients (HR = 1.38).53 In PV patients, the ECLAP study reported a reduction of thrombosis incidence (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) with no significant increase of bleeding with aspirin.43 No such randomized study has been done in ET. On the other hand, a retrospective study did not show any positive impact of aspirin as primary prophylaxis on the reduction of thrombosis in low-risk ET patients.35 Furthermore, in low-risk CALR-mutated ET, aspirin did not reduce thrombosis risk but it increased bleeding risk (p = 0.03).39 A 2017 meta-analysis reported an uncertain benefit–risk ratio of antiplatelet drugs in ET patients.60 The possible absence of impact of aspirin on thrombosis and bleeding risk may be due to an insufficient control of platelet COX-1 activity with a once-daily low dose of aspirin.67

Studies on VKAs or DOACs are also lacking in this population. Such studies have been conducted in the general population, e.g., VKAs versus placebo,50 DOACs versus VKAs,51,52 and the combination of DOAC and aspirin versus DOAC and placebo.58 All of these treatments increased bleeding risk. This was also true in a population with cancer, with a particular gastrointestinal predominance for DOACs.69 Studies about DOACs in MPN patients are required to assess their bleeding risk.

Increased risk of both thrombosis and bleeding may be chronologically dissociated. A retrospective study in a German MPN registry showed that thrombosis events occurred mostly around the time of diagnosis, and the number of events seemed to decrease with time, in contrast to bleeding incidence, which was constant over time.23 The duration of follow-up was analyzed as a bleeding risk factor in three studies,18,46,47 and bleeding-free survival seemed to continually decrease with time in another cohort of ET and PV patients.16 The ongoing FAST trial (from the French FIM group) challenges the need of...
aspirin in ET patients treated with hydroxyurea depending on the hematological response (NCT02611973). The bleeding risk of anticoagulant drugs as a time-dependent variable must be studied.

The CNS and GIT are already known as frequent sites of MB.\(^\text{10}\) Cerebral hemorrhages must be feared, as they result in the most deaths due to bleeding. For example, in 13,559 non-MPN patients followed for a median period of 2.4 years and receiving VKA for atrial nonvalvular fibrillation, 35 out of 72 (48.6\%) cerebral bleeding events were lethal.\(^\text{71}\) The GIT often bleeds and rarely kills, but it can cause unscheduled hospitalizations and blood transfusions.

Proposed bleeding management strategies in MPNs have been recently published: (1) AWS testing prior to aspirin when platelet counts are \(>1,000 \times 10^9/L\) and the consideration of testing even with modest thrombocytosis, (2) cytorreduction to a lower platelet count in the presence of AWS, (3) supportive measures such as desmopressin and von Willebrand factor concentrates in AWS, (4) empirical platelet transfusion if bleeding is suspected to be due to qualitative platelet dysfunction, and (5) collaboration with a hemophilia specialist if there are questions regarding AWS testing/management.\(^\text{9}\)

To conclude, bleeding risk of ET/PV patients should not be underestimated because of the high fatality rates, even compared with bleeding fatality rates in cancer patients with anticoagulant drugs.

First, to help physicians better understand the bleeding risk of MPN patients, future studies should be more accurate and homogeneous. They could use the ISTH classification, which is reproducible, practical, and already used in anticoagulant drug trials. Each event should be classified (major, CRNMB, and possibly minor) and incidence should be expressed as \% patients/year to equalize for the number of years.

Second, future studies should be more homogeneous to better identify bleeding risk factors. Among them, age, splenomegaly, history of hemorrhage, platelet count, and MPN subtypes at diagnosis should be focused on. Cytorreductive and antithrombotic drugs did not seem to influence bleeding profiles, but they should be evaluated as time-dependent variables. Prospective studies are still needed.

Finally, provoked bleeding (trauma, surgery, etc.) is not infrequent and could be prevented or reduced, for example, by tranexamic acid. Collaborations between surgeons and hematologists need to be improved.

Authors’ Contributions
C.N., J.-C.I., B.P.-P., and K.L. elaborated the study. C.N. did the PubMed analysis. C.N. and J.-C.I. wrote the manuscript. B.P.-P., K.L., and E.L. reviewed the manuscript. All the authors have validated the final version of the manuscript.

Conflict of Interest
None declared.

Acknowledgments
The authors would like to thank the French GOAL group for its precious help.

References

Thrombosis and Haemostasis
Bleeding in Essential Thrombocythemia and Polycythemia Vera

Nicol et al.


26 Rumi E, Boveri E, Bellini M, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigatori. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 2017;8(60):101735–101744


50 Singer DE, Hughes RA, Gress DR, et al; Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-